Ziopharm, Intrexon tackle CAR-T in expanded partnership

Proving once again that CAR-T is now one of the hottest fields in cancer drug development, Boston-based Ziopharm Oncology ($ZIOP) is expanding its R&D collaboration with Intrexon ($XON) to include the personalized immuno-oncology technology. In CAR-T, a patient's T cells are extracted, reengineered with chimeric antigen receptors to launch a personalized immune system attack on specific cancer cells and then reinjected into patients, where they can repopulate to fight cancer. Intrexon boasts that its industrial engineering expertise will help resolve some of the lingering questions regarding toxicity, side effects and manufacturing efficiency. Right now the two are in the preclinical stage and plan to update the program later this year. The partnership between Intrexon and Ziopharm dates back to early 2011. Last year Ziopharm was hit hard after its lead drug failed in Phase III. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.